Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

GREB1 amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistance.

Lee E, Wongvipat J, Choi D, Wang P, Lee YS, Zheng D, Watson PA, Gopalan A, Sawyers CL.

Elife. 2019 Jan 15;8. pii: e41913. doi: 10.7554/eLife.41913.

2.

COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors.

Xie Y, Cao Z, Wong EW, Guan Y, Ma W, Zhang JQ, Walczak EG, Murphy D, Ran L, Sirota I, Wang S, Shukla S, Gao D, Knott SR, Chang K, Leu J, Wongvipat J, Antonescu CR, Hannon G, Chi P, Chen Y.

J Clin Invest. 2018 Apr 2;128(4):1442-1457. doi: 10.1172/JCI94840. Epub 2018 Mar 5.

3.

Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance.

Shukla S, Cyrta J, Murphy DA, Walczak EG, Ran L, Agrawal P, Xie Y, Chen Y, Wang S, Zhan Y, Li D, Wong EWP, Sboner A, Beltran H, Mosquera JM, Sher J, Cao Z, Wongvipat J, Koche RP, Gopalan A, Zheng D, Rubin MA, Scher HI, Chi P, Chen Y.

Cancer Cell. 2017 Dec 11;32(6):792-806.e7. doi: 10.1016/j.ccell.2017.10.008. Epub 2017 Nov 16.

4.

Deletion of 3p13-14 locus spanning FOXP1 to SHQ1 cooperates with PTEN loss in prostate oncogenesis.

Hieronymus H, Iaquinta PJ, Wongvipat J, Gopalan A, Murali R, Mao N, Carver BS, Sawyers CL.

Nat Commun. 2017 Oct 20;8(1):1081. doi: 10.1038/s41467-017-01198-9.

5.

Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer.

Shah N, Wang P, Wongvipat J, Karthaus WR, Abida W, Armenia J, Rockowitz S, Drier Y, Bernstein BE, Long HW, Freedman ML, Arora VK, Zheng D, Sawyers CL.

Elife. 2017 Sep 11;6. pii: e27861. doi: 10.7554/eLife.27861.

6.

ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis.

Bose R, Karthaus WR, Armenia J, Abida W, Iaquinta PJ, Zhang Z, Wongvipat J, Wasmuth EV, Shah N, Sullivan PS, Doran MG, Wang P, Patruno A, Zhao Y; International SU2C/PCF Prostate Cancer Dream Team, Zheng D, Schultz N, Sawyers CL.

Nature. 2017 Jun 29;546(7660):671-675. doi: 10.1038/nature22820. Epub 2017 Jun 14.

7.

SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.

Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, Wongvipat J, Ku SY, Gao D, Cao Z, Shah N, Adams EJ, Abida W, Watson PA, Prandi D, Huang CH, de Stanchina E, Lowe SW, Ellis L, Beltran H, Rubin MA, Goodrich DW, Demichelis F, Sawyers CL.

Science. 2017 Jan 6;355(6320):84-88. doi: 10.1126/science.aah4307.

8.

Applying ⁸⁹Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins.

Doran MG, Carnazza KE, Steckler JM, Spratt DE, Truillet C, Wongvipat J, Sawyers CL, Lewis JS, Evans MJ.

Mol Pharm. 2016 Feb 1;13(2):683-8. doi: 10.1021/acs.molpharmaceut.5b00882. Epub 2016 Jan 12.

9.

Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation.

Spratt DE, Evans MJ, Davis BJ, Doran MG, Lee MX, Shah N, Wongvipat J, Carnazza KE, Klee GG, Polkinghorn W, Tindall DJ, Lewis JS, Sawyers CL.

Cancer Res. 2015 Nov 15;75(22):4688-96. doi: 10.1158/0008-5472.CAN-15-0892. Epub 2015 Oct 2.

10.

Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth.

Ran L, Sirota I, Cao Z, Murphy D, Chen Y, Shukla S, Xie Y, Kaufmann MC, Gao D, Zhu S, Rossi F, Wongvipat J, Taguchi T, Tap WD, Mellinghoff IK, Besmer P, Antonescu CR, Chen Y, Chi P.

Cancer Discov. 2015 Mar;5(3):304-15. doi: 10.1158/2159-8290.CD-14-0985. Epub 2015 Jan 8.

11.

Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.

Schwartz S, Wongvipat J, Trigwell CB, Hancox U, Carver BS, Rodrik-Outmezguine V, Will M, Yellen P, de Stanchina E, Baselga J, Scher HI, Barry ST, Sawyers CL, Chandarlapaty S, Rosen N.

Cancer Cell. 2015 Jan 12;27(1):109-22. doi: 10.1016/j.ccell.2014.11.008. Epub 2014 Dec 24.

12.

Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET.

Doran MG, Watson PA, Cheal SM, Spratt DE, Wongvipat J, Steckler JM, Carrasquillo JA, Evans MJ, Lewis JS.

J Nucl Med. 2014 Dec;55(12):2045-9. doi: 10.2967/jnumed.114.145185. Epub 2014 Nov 5.

13.

Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling.

Wanjala J, Taylor BS, Chapinski C, Hieronymus H, Wongvipat J, Chen Y, Nanjangud GJ, Schultz N, Xie Y, Liu S, Lu W, Yang Q, Sander C, Chen Z, Sawyers CL, Carver BS.

Mol Cancer Ther. 2015 Jan;14(1):278-88. doi: 10.1158/1535-7163.MCT-14-0542-T. Epub 2014 Nov 7.

14.

MAGI-2 scaffold protein is critical for kidney barrier function.

Balbas MD, Burgess MR, Murali R, Wongvipat J, Skaggs BJ, Mundel P, Weins A, Sawyers CL.

Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14876-81. doi: 10.1073/pnas.1417297111. Epub 2014 Sep 30.

15.

Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries.

Doran MG, Spratt DE, Wongvipat J, Ulmert D, Carver BS, Sawyers CL, Evans MJ.

Mol Imaging. 2014;13. doi: 10.2310/7290.2014.00026.

16.

Organoid cultures derived from patients with advanced prostate cancer.

Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora VK, Wongvipat J, Kossai M, Ramazanoglu S, Barboza LP, Di W, Cao Z, Zhang QF, Sirota I, Ran L, MacDonald TY, Beltran H, Mosquera JM, Touijer KA, Scardino PT, Laudone VP, Curtis KR, Rathkopf DE, Morris MJ, Danila DC, Slovin SF, Solomon SB, Eastham JA, Chi P, Carver B, Rubin MA, Scher HI, Clevers H, Sawyers CL, Chen Y.

Cell. 2014 Sep 25;159(1):176-187. doi: 10.1016/j.cell.2014.08.016. Epub 2014 Sep 4.

17.

Identification of multipotent luminal progenitor cells in human prostate organoid cultures.

Karthaus WR, Iaquinta PJ, Drost J, Gracanin A, van Boxtel R, Wongvipat J, Dowling CM, Gao D, Begthel H, Sachs N, Vries RGJ, Cuppen E, Chen Y, Sawyers CL, Clevers HC.

Cell. 2014 Sep 25;159(1):163-175. doi: 10.1016/j.cell.2014.08.017. Epub 2014 Sep 4.

18.

Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.

Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers CL.

Cell. 2013 Dec 5;155(6):1309-22. doi: 10.1016/j.cell.2013.11.012.

19.

Androgen receptor signaling regulates DNA repair in prostate cancers.

Polkinghorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ, Arora VK, Yen WF, Cai L, Zheng D, Carver BS, Chen Y, Watson PA, Shah NP, Fujisawa S, Goglia AG, Gopalan A, Hieronymus H, Wongvipat J, Scardino PT, Zelefsky MJ, Jasin M, Chaudhuri J, Powell SN, Sawyers CL.

Cancer Discov. 2013 Nov;3(11):1245-53. doi: 10.1158/2159-8290.CD-13-0172. Epub 2013 Sep 11.

20.

ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss.

Chen Y, Chi P, Rockowitz S, Iaquinta PJ, Shamu T, Shukla S, Gao D, Sirota I, Carver BS, Wongvipat J, Scher HI, Zheng D, Sawyers CL.

Nat Med. 2013 Aug;19(8):1023-9. doi: 10.1038/nm.3216. Epub 2013 Jun 30.

21.

Overcoming mutation-based resistance to antiandrogens with rational drug design.

Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, Greene GL, Shen Y, Sawyers CL.

Elife. 2013 Apr 9;2:e00499. doi: 10.7554/eLife.00499.

22.

Annotating MYC status with 89Zr-transferrin imaging.

Holland JP, Evans MJ, Rice SL, Wongvipat J, Sawyers CL, Lewis JS.

Nat Med. 2012 Oct;18(10):1586-91. doi: 10.1038/nm.2935. Epub 2012 Sep 23.

23.

Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.

Ulmert D, Evans MJ, Holland JP, Rice SL, Wongvipat J, Pettersson K, Abrahamsson PA, Scardino PT, Larson SM, Lilja H, Lewis JS, Sawyers CL.

Cancer Discov. 2012 Apr;2(4):320-7. doi: 10.1158/2159-8290.CD-11-0316. Epub 2012 Mar 31.

24.

ARN-509: a novel antiandrogen for prostate cancer treatment.

Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH.

Cancer Res. 2012 Mar 15;72(6):1494-503. doi: 10.1158/0008-5472.CAN-11-3948. Epub 2012 Jan 20.

25.

Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.

Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, Larson SM, Sawyers CL.

Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9578-82. doi: 10.1073/pnas.1106383108. Epub 2011 May 23.

26.

Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.

Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL.

Cancer Cell. 2011 May 17;19(5):575-86. doi: 10.1016/j.ccr.2011.04.008.

27.

MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors.

Clegg NJ, Couto SS, Wongvipat J, Hieronymus H, Carver BS, Taylor BS, Ellwood-Yen K, Gerald WL, Sander C, Sawyers CL.

PLoS One. 2011 Mar 4;6(3):e17449. doi: 10.1371/journal.pone.0017449.

28.

ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours.

Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, Fletcher JA, Dewell S, Maki RG, Zheng D, Antonescu CR, Allis CD, Sawyers CL.

Nature. 2010 Oct 14;467(7317):849-53. doi: 10.1038/nature09409. Epub 2010 Oct 3.

29.

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.

Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL.

Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16759-65. doi: 10.1073/pnas.1012443107. Epub 2010 Sep 7.

30.

Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC).

Jung ME, Ouk S, Yoo D, Sawyers CL, Chen C, Tran C, Wongvipat J.

J Med Chem. 2010 Apr 8;53(7):2779-96. doi: 10.1021/jm901488g.

31.

Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis.

King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS, Gerald WL, Sawyers CL.

Nat Genet. 2009 May;41(5):524-6. doi: 10.1038/ng.371. Epub 2009 Apr 26.

32.

Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL.

Science. 2009 May 8;324(5928):787-90. doi: 10.1126/science.1168175. Epub 2009 Apr 9.

33.

Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens.

Ellwood-Yen K, Wongvipat J, Sawyers C.

Cancer Res. 2006 Nov 1;66(21):10513-6.

34.

Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.

Watson PA, Ellwood-Yen K, King JC, Wongvipat J, Lebeau MM, Sawyers CL.

Cancer Res. 2005 Dec 15;65(24):11565-71.

35.

HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.

Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL.

Cancer Cell. 2004 Nov;6(5):517-27.

36.

Myc-driven murine prostate cancer shares molecular features with human prostate tumors.

Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV, Sawyers CL.

Cancer Cell. 2003 Sep;4(3):223-38. Erratum in: Cancer Cell. 2005 Dec;8(6):485.

Supplemental Content

Loading ...
Support Center